GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (NAS:VRTX) » Definitions » Cyclically Adjusted PS Ratio

VRTX (Vertex Pharmaceuticals) Cyclically Adjusted PS Ratio : 17.93 (As of Jul. 06, 2025)


View and export this data going back to 1991. Start your Free Trial

What is Vertex Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2025-07-06), Vertex Pharmaceuticals's current share price is $459.62. Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $25.63. Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 17.93.

The historical rank and industry rank for Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

VRTX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 14.8   Med: 23.7   Max: 43.87
Current: 17.93

During the past years, Vertex Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 43.87. The lowest was 14.80. And the median was 23.70.

VRTX's Cyclically Adjusted PS Ratio is ranked worse than
80% of 490 companies
in the Biotechnology industry
Industry Median: 5.685 vs VRTX: 17.93

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2025 was $10.675. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $25.63 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Vertex Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.88 17.19 17.86 20.54 16.56

Vertex Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.78 21.11 20.01 16.56 18.92

Competitive Comparison of Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


;
;

Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=459.62/25.63
=17.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Vertex Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=10.675/134.9266*134.9266
=10.675

Current CPI (Mar. 2025) = 134.9266.

Vertex Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.690 100.684 0.925
201509 1.280 100.392 1.720
201512 1.720 99.792 2.326
201603 1.633 100.470 2.193
201606 1.765 101.688 2.342
201609 1.689 101.861 2.237
201612 1.871 101.863 2.478
201703 2.874 102.862 3.770
201706 2.162 103.349 2.823
201709 2.310 104.136 2.993
201712 2.539 104.011 3.294
201803 2.479 105.290 3.177
201806 2.909 106.317 3.692
201809 3.020 106.507 3.826
201812 3.349 105.998 4.263
201903 3.299 107.251 4.150
201906 3.623 108.070 4.523
201909 3.647 108.329 4.542
201912 5.389 108.420 6.707
202003 5.750 108.902 7.124
202006 5.788 108.767 7.180
202009 5.825 109.815 7.157
202012 6.225 109.897 7.643
202103 6.584 111.754 7.949
202106 6.871 114.631 8.087
202109 7.640 115.734 8.907
202112 8.068 117.630 9.254
202203 8.133 121.301 9.047
202206 8.489 125.017 9.162
202209 8.995 125.227 9.692
202212 8.846 125.222 9.532
202303 9.123 127.348 9.666
202306 9.575 128.729 10.036
202309 9.530 129.860 9.902
202312 9.654 129.419 10.065
202403 10.305 131.776 10.551
202406 10.250 132.554 10.433
202409 10.620 133.029 10.771
202412 11.318 133.157 11.468
202503 10.675 134.927 10.675

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vertex Pharmaceuticals  (NAS:VRTX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Executives
David Altshuler officer: EVP, Global Research and CSO C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Sangeeta N. Bhatia director C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Ourania Tatsis officer: EVP, Chief Reg. & Quality Off. C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Wagner Charles F Jr officer: EVP & Chief Financial Officer C/O MILLIPORE CORP, BILLERICA MA 01820
Atkinson Edward Morrow Iii officer: EVP, Chief Technical Ops. Off. C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104
Kristen Ambrose officer: SVP & Chief Accounting Officer C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON MA 02210
Jonathan Biller officer: EVP and Chief Legal Officer C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Reshma Kewalramani director, officer: CEO & President C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Jeffrey M Leiden director 15 N BEACH ROAD, HOBE SOUND FL 33455
Carmen Bozic officer: EVP and CMO C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Bruce I Sachs director C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Stuart A Arbuckle officer: EVP, COO VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139
Amit Sachdev officer: SVP, Public Policy,Gov Affairs C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Michel Lagarde director 450 LEXINGTON AVE., 31ST FLOOR, NEW YORK NY 10017
Terrence C Kearney director IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045